Literature DB >> 18329227

Improving acceptance of naltrexone in community addiction treatment centers: a pilot study.

Suzanne E Thomas1, Peter M Miller, Patrick K Randall, Sarah W Book.   

Abstract

Alcoholism pharmacotherapies are underused in community addiction treatment settings, in part because individuals who practice in these settings--nonmedical addiction counselors and administrators--lack knowledge about and confidence in the value of adjunctive alcohol pharmacotherapies. We developed and tested an intervention to improve knowledge and attitudes about naltrexone. A team of researchers, physicians, addiction treatment counselors, and administrators collaborated to develop a naltrexone educational intervention designed for nonmedical addiction professionals. The intervention was compared with a control condition in a pilot study with 6 addiction treatment agencies (3 agencies per group). Participants (counselors and administrators, N = 84) were assessed before and 6 months after the intervention. Results revealed that the intervention significantly improved naltrexone knowledge, and participants who received the intervention reported greater satisfaction with the education they received, as well as greater use of the information. The effect of the intervention on attitudes about naltrexone was encouraging but did not to reach statistical significance. This study is the first reported attempt to develop and test an intervention specifically to improve acceptance of adjunctive medications for alcoholism among nonmedical addiction professionals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329227      PMCID: PMC2612537          DOI: 10.1016/j.jsat.2007.11.001

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  16 in total

1.  Staff beliefs about addiction treatment.

Authors:  R F Forman; G Bovasso; G Woody
Journal:  J Subst Abuse Treat       Date:  2001-07

2.  Technology transfer and the treatment of addiction: what can research offer practice?

Authors:  A Thomas McLellan
Journal:  J Subst Abuse Treat       Date:  2002-06

3.  Retaining counseling staff at substance abuse treatment centers: effects of management practices.

Authors:  Hannah K Knudsen; J Aaron Johnson; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2003-03

4.  Can the national addiction treatment infrastructure support the public's demand for quality care?

Authors:  A Thomas McLellan; Deni Carise; Herbert D Kleber
Journal:  J Subst Abuse Treat       Date:  2003-09

5.  Curative factors in alcohol and drug treatment: behavioral and disease model perspectives.

Authors:  J Morgenstern; B S McCrady
Journal:  Br J Addict       Date:  1992-06

6.  Adoption of naltrexone to treat alcohol dependence.

Authors:  Bret E Fuller; Traci Rieckmann; Dennis McCarty; Kevin W Smith; Helen Levine
Journal:  J Subst Abuse Treat       Date:  2005-04

Review 7.  Opioid antagonists for alcohol dependence.

Authors:  M Srisurapanont; N Jarusuraisin
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

8.  Research to practice: adoption of naltrexone in alcoholism treatment.

Authors:  Cindy Parks Thomas; Stanley S Wallack; Sue Lee; Dennis McCarty; Robert Swift
Journal:  J Subst Abuse Treat       Date:  2003-01

Review 9.  Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.

Authors:  Carmen Bouza; Magro Angeles; Angeles Magro; Ana Muñoz; José María Amate
Journal:  Addiction       Date:  2004-07       Impact factor: 6.526

10.  Use of naltrexone in the treatment of alcoholism nationally in the Department of Veterans Affairs.

Authors:  Ismene L Petrakis; Douglas Leslie; Robert Rosenheck
Journal:  Alcohol Clin Exp Res       Date:  2003-11       Impact factor: 3.455

View more
  11 in total

1.  Advancing recovery: implementing evidence-based treatment for substance use disorders at the systems level.

Authors:  Laura A Schmidt; Traci Rieckmann; Amanda Abraham; Todd Molfenter; Victor Capoccia; Paul Roman; David H Gustafson; Dennis McCarty
Journal:  J Stud Alcohol Drugs       Date:  2012-05       Impact factor: 2.582

2.  The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.

Authors:  Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2010-02-01

3.  Brief Training on Medication-Assisted Treatment Improves Community Mental Health Clinicians' Confidence and Readiness to Address Substance Use Disorders.

Authors:  Theddeus Iheanacho; Tanner Bommersbach; Brian Fuehrlein; Bachaar Arnaout; Charles Dike
Journal:  Community Ment Health J       Date:  2020-02-15

Review 4.  Medications development to treat alcohol dependence: a vision for the next decade.

Authors:  Raye Z Litten; Mark Egli; Markus Heilig; Changhai Cui; Joanne B Fertig; Megan L Ryan; Daniel E Falk; Howard Moss; Robert Huebner; Antonio Noronha
Journal:  Addict Biol       Date:  2012-03-28       Impact factor: 4.280

5.  Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector.

Authors:  Amanda J Abraham; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2010-05       Impact factor: 2.582

6.  Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach.

Authors:  Amanda J Abraham; Traci Rieckmann; Thomas McNulty; Anne E Kovas; Paul M Roman
Journal:  Addict Behav       Date:  2011-01-28       Impact factor: 3.913

7.  Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.

Authors:  Lydia Aletraris; Mary Bond Edmond; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2015-01       Impact factor: 2.582

8.  Counselor attitudes toward pharmacotherapies for alcohol dependence.

Authors:  Amanda J Abraham; Lori J Ducharme; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2009-07       Impact factor: 2.582

Review 9.  Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development.

Authors:  Raye Z Litten; Daniel E Falk; Megan L Ryan; Joanne B Fertig
Journal:  Alcohol Clin Exp Res       Date:  2016-05-17       Impact factor: 3.455

10.  A qualitative study of the adoption of buprenorphine for opioid addiction treatment.

Authors:  Carla A Green; Dennis McCarty; Jennifer Mertens; Frances L Lynch; Anadam Hilde; Alison Firemark; Constance M Weisner; David Pating; Bradley M Anderson
Journal:  J Subst Abuse Treat       Date:  2013-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.